GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Insider Ownership

Microba Life Sciences (ASX:MAP) Insider Ownership : 0.00 % (As of Dec. 15, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Microba Life Sciences's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Microba Life Sciences's Institutional Ownership is 1.02%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Microba Life Sciences's Float Percentage Of Total Shares Outstanding is 0.00%.


Microba Life Sciences Insider Ownership Historical Data

The historical data trend for Microba Life Sciences's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences Insider Ownership Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24
Insider Ownership
- - -

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Insider Ownership Get a 7-Day Free Trial - - - - -

Microba Life Sciences Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Microba Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are; Testing Services and Supplements which derives key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.

Microba Life Sciences Headlines

No Headlines